Chilly and flu drugs together with NyQuil sit on a retailer shelf in Miami on Sept. 12, 2023.
Joe Raedle | Getty Photos
CVS is eradicating among the commonest cough and chilly medicines from its retailer cabinets and can now not promote them, an organization spokesperson informed CNBC on Thursday.
The corporate’s determination comes a month after a panel of advisors to the Meals and Drug Administration unanimously decided that the primary ingredient utilized in many well-liked over-the-counter chilly and allergy medicines would not truly work to clear up congested noses when taken orally.
The FDA has not determined whether or not to ask drug producers and retailers reminiscent of CVS to take away merchandise containing oral phenylephrine — a nasal decongestant present in variations of medication reminiscent of NyQuil, Benadryl, Sudafed and Mucinex — from the market.
Nonetheless, CVS is voluntarily eradicating sure cough and chilly medicines that comprise phenylephrine as the one lively ingredient from shops.
CVS is conscious of the dedication made by the FDA advisors and can comply with instructions from the company to make sure that merchandise bought on the firm’s shops adjust to legal guidelines and laws, the spokesperson stated. They added that CVS shops will proceed to supply different oral cough and chilly merchandise to satisfy affected person wants.
Oral merchandise that listing phenylephrine as its solely lively ingredient embrace Sudafed PE, which is marketed by Johnson & Johnson’s shopper well being spinoff Kenvue. Kenvue didn’t instantly reply to CNBC’s request for remark about CVS’s determination.
The Wall Avenue Journal first reported on CVS’ determination Thursday.
Pulling oral phenylephrine from the market solely may have an effect on CVS and different retail pharmacy chains, which rake in income from promoting over-the-counter chilly and allergy tablets.
Retail shops within the U.S. bought 242 million bottles of medication containing phenylephrine final 12 months, up 30% from 2021, in response to information compiled by FDA employees. These bottles generated $1.8 billion in gross sales final 12 months, the info stated.
With out oral phenylephrine, sufferers may also doubtless be pressured to hunt out liquid and spray variations of the medication or solely new medicines, which weren’t included within the evaluate by the FDA advisors.
Do not miss these CNBC PRO tales: